Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)
Maxcyte (MXCT) posted quarterly Non-Current Deffered Revenue of $344600.0 for Q3 2022, down 23.46% quarter-over-quarter from $450200.0 in Q4 2021.
Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022) Analysis & Trends
Maxcyte (MXCT) has reported Non-Current Deffered Revenue for 2 consecutive years, with $344600.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue changed N/A year-over-year to $344600.0; the TTM figure through Sep 2022 stood at $344600.0 (changed N/A YoY), while the FY2021 annual figure was $450200.0, changed N/A from the prior year.
- Non-Current Deffered Revenue fell to $344600.0 in Q3 2022 per MXCT's latest filing, from $450200.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $450200.0 in Q4 2021 and bottomed at $344600.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.52 Bn | 193.92 Bn | 7.27 Bn | - |
| 2 | Stryker | 129.55 Bn | 126.07 Bn | 4.50 Bn | - |
| 3 | Medtronic | 119.60 Bn | 110.38 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 73.64 Bn | 73.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 52.33 Bn | 48.08 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.69 Bn | 32.74 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 34.10 Bn | 31.99 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.43 Bn | 23.11 Bn | 4.55 Bn | 539.34 Mn |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | - |
| 10 | Maxcyte | 147.95 Mn | 147.95 Mn | 5.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 344,600.00 |
| Dec 31, 2021 | 450,200.00 |